Medicine and Dentistry
TNF Inhibitor
100%
Inflammatory Bowel Disease
100%
Tumor Necrosis Factor
100%
Patient with Inflammatory Bowel Disease
66%
Adalimumab
66%
Ulcerative Colitis
66%
Crohn's Disease
66%
Infliximab
66%
Golimumab
33%
Certolizumab Pegol
33%
Specific Tumor
33%
Keyphrases
Inflammatory Bowel Disease
100%
Tumour Necrosis Factor Inhibitor (TNFi)
100%
Anti-tumor Necrosis Factor Therapy
100%
Infliximab
66%
Adalimumab
66%
Golimumab
33%
Conventional Treatment
33%
Crohn's Disease
33%
Certolizumab Pegol
33%
Therapeutic Benefits
33%
Extraintestinal Manifestations
33%
Ulcerative Colitis
33%
Crohn's Colitis
33%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor
100%
Inflammatory Bowel Disease
100%
Tumor Necrosis Factor Inhibitor
75%
Crohn's Disease
50%
Ulcerative Colitis
50%
Adalimumab
50%
Infliximab
50%
Golimumab
25%
Certolizumab Pegol
25%
Immunology and Microbiology
Tumor Necrosis Factor
100%
Inflammatory Bowel Disease
100%
TNF Inhibitor
75%
Infliximab
50%
Adalimumab
50%
Ulcerative Colitis
50%
Crohn's Disease
50%
Golimumab
25%